Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

SHOCKING: Axonics - What They Never Told You

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022

Upgrades

Benzinga · Oct 12, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022

Upgrades

Benzinga · Oct 10, 2022

Analyst Ratings for Axonics

Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings:

Benzinga · May 6, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022

Upgrades

Benzinga · Apr 6, 2022

FDA Approves Axonics' Recharge-Free Sacral Neuromodulation System

The

Benzinga · Mar 8, 2022

Analyst Ratings For Axonics

Axonics (NASDAQ:AXNX) has observed the following analyst ratings within the last quarter:

Benzinga · Feb 25, 2022

Axonics: Q4 Earnings Insights

Axonics (NASDAQ:AXNX) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Axonics beat estimated earnings by 8.11%, reporting an EPS of $-0.34 versus an estimate of $-0.37.

Benzinga · Feb 24, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

REIT

535 stories

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.